US FDA moves to court against Ranbaxy

American health regulator USFDA has filed a motion in a US court seeking 'certain' documents from Ranbaxy, amid reports of systematic fraudulent conduct, which the company denied.

"No legal proceeding has been initiated against us and we continue to co-operate with the department of justice," a company spokesperson told a news agency.

The spokesperson, however, admitted that USFDA had filed a motion in a US court seeking certain documents.

The spokesperson refused to disclose as to what the USFDA was seeking clarifications on from the company.

A section of the media has reported that USFDA has taken Ranbaxy to the court for systematic fraudulent conduct and has asked the court to force Ranbaxy to internally review the manufacturing operations.

The spokesperson said Ranbaxy will remain committed to supply high quality generic medicine at affordable prices the to US customers , the spokesperson added.